No Data
No Data
Zhaoyan Pharmaceutical (06127) plans to distribute 2023 cash dividends of 0.16 yuan per share
Zhaoyan Pharmaceutical (06127) announced that it intends to distribute a 2023 cash dividend of RMB 0.16 per share (including...
JOINN: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
Zhaoyan Pharmaceutical (603127.SH) released 2023 results, net profit of 397 million yuan, a year-on-year decrease of 63.04%
Zhaoyan New Pharmaceutical (603127.SH) released its 2023 annual report, achieving operating revenue of 2,376 billion yuan,...
Medication heats up strongly! Pharmaceutical stocks are rebounding, and the US “Biosafety Act” suddenly becomes a variable?
Also boosted by these factors!
Changes in Hong Kong stocks | CRO concept stocks generally fall in early trading, Kant expects this year's revenue growth to hit a ten-year low, Citi says the guidelines are disappointing
CRO concept stocks generally declined in early trading. As of press release, Pharmaceuticals (02359) fell 4.86% to HK$38.2; Tiger Pharmaceuticals (03347) fell 4.48% to HK$29.85; Zhaoyan Pharmaceutical (06127) fell 4.47% to HK$9.18; Kanglong Chemical (03759) fell 4.21% to HK$9.79.
Changes in Hong Kong stocks | Yao Ming Kangde (02359) once fell nearly 10%, leading a decline in CRO concept stocks last year's revenue exceeding 40 billion dollars, and growth still depended on the European and American markets
CRO concept stocks had the highest decline. As of press release, Pharmacovich (02359) fell 7.6% to HK$39.5; Kingsley Biotech (01548) fell 5.73% to HK$15.78; and Kanglong Chemical (03759) fell 3.54% to HK$10.34.
No Data